{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["DePeaux K"],"funding":["NIAID NIH HHS","National Institutes of Health","Alliance for Cancer Gene Therapy","National Institute of General Medical Sciences","Cancer Research Institute","University of Pittsburgh Medical Center","Stand Up to Cancer","Hillman Fellows for Innovative Cancer Research Program","Mark Foundation For Cancer Research","National Cancer Institute","NCI NIH HHS","NIGMS NIH HHS","American Association for Cancer Research"],"pagination":["e20230053"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10407786"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["220(10)"],"pubmed_abstract":["While checkpoint blockade immunotherapies have widespread success, they rely on a responsive immune infiltrate; as such, treatments enhancing immune infiltration and preventing immunosuppression are of critical need. We previously generated αPD-1 resistant variants of the murine HNSCC model MEER. While entirely αPD-1 resistant, these tumors regress after single dose of oncolytic vaccinia virus (VV). We then generated a VV-resistant MEER line to dissect the immunologic features of sensitive and resistant tumors. While treatment of both tumor types induced immune infiltration and IFNγ, we found a defining feature of resistance was elevation of immunosuppressive cytokines like TGFβ, which blunted IFNγ signaling, especially in regulatory T cells. We engineered VV to express a genetically encod"],"journal":["The Journal of experimental medicine"],"pubmed_title":["An oncolytic virus-delivered TGFβ inhibitor overcomes the immunosuppressive tumor microenvironment."],"pmcid":["PMC10407786"],"funding_grant_id":["GM58670","DP2 AI136598","P30CA047904","DP2AI136598","SU2C-AACR-IRG-04-16","T32-CA082084","P50CA097190","R01 GM058670","R01 AI171483","R01 CA233622","F31-CA247129","P50 CA121973","R01AI171483","P30 CA047904","P50 CA097190","P50CA121973","T32 CA082084","F31 CA247129","T32 AI089443","CA233622"],"pubmed_authors":["Lontos K","Gunn WG","Thorne SH","Wieteska L","Hinck AP","DePeaux K","Watson MJ","Yao T","Dean VG","Delgoffe GM","Wilfahrt D","Hinck C","Rivadeneira DB"],"additional_accession":[]},"is_claimable":false,"name":"An oncolytic virus-delivered TGFβ inhibitor overcomes the immunosuppressive tumor microenvironment.","description":"While checkpoint blockade immunotherapies have widespread success, they rely on a responsive immune infiltrate; as such, treatments enhancing immune infiltration and preventing immunosuppression are of critical need. We previously generated αPD-1 resistant variants of the murine HNSCC model MEER. While entirely αPD-1 resistant, these tumors regress after single dose of oncolytic vaccinia virus (VV). We then generated a VV-resistant MEER line to dissect the immunologic features of sensitive and resistant tumors. While treatment of both tumor types induced immune infiltration and IFNγ, we found a defining feature of resistance was elevation of immunosuppressive cytokines like TGFβ, which blunted IFNγ signaling, especially in regulatory T cells. We engineered VV to express a genetically encod","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Oct","modification":"2026-04-29T02:25:47.804Z","creation":"2025-04-21T15:03:02.735Z"},"accession":"S-EPMC10407786","cross_references":{"pubmed":["37552475"],"doi":["10.1084/jem.20230053"]}}